WallStSmart

Hologic Inc (HOLX)vsResMed Inc (RMD)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

ResMed Inc generates 37% more annual revenue ($5.65B vs $4.13B). RMD leads profitability with a 27.0% profit margin vs 13.2%. RMD appears more attractively valued with a PEG of 1.33. RMD earns a higher WallStSmart Score of 65/100 (C+).

HOLX

Buy

51

out of 100

Grade: C-

Growth: 2.7Profit: 6.5Value: 4.3Quality: 8.0
Piotroski: 5/9Altman Z: 2.37

RMD

Buy

65

out of 100

Grade: C+

Growth: 6.0Profit: 9.0Value: 4.7Quality: 9.0
Piotroski: 5/9Altman Z: 4.53
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for HOLX.

RMDSignificantly Overvalued (-24.1%)

Margin of Safety

-24.1%

Fair Value

$209.18

Current Price

$224.99

$15.81 premium

UndervaluedFair: $209.18Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

HOLX1 strengths · Avg: 8.0/10
Operating MarginProfitability
23.0%8/10

Strong operational efficiency at 23.0%

RMD6 strengths · Avg: 9.2/10
Operating MarginProfitability
30.9%10/10

Strong operational efficiency at 30.9%

Altman Z-ScoreHealth
4.5310/10

Safe zone — low bankruptcy risk

Return on EquityProfitability
23.1%9/10

Every $100 of equity generates 23 in profit

Profit MarginProfitability
27.0%9/10

Keeps 27 of every $100 in revenue as profit

Debt/EquityHealth
0.139/10

Conservative balance sheet, low leverage

Free Cash FlowQuality
$1.65B8/10

Generating 1.6B in free cash flow

Areas to Watch

HOLX4 concerns · Avg: 3.5/10
PEG RatioValuation
1.664/10

Expensive relative to growth rate

P/E RatioValuation
31.5x4/10

Premium valuation, high expectations priced in

Revenue GrowthGrowth
2.5%4/10

2.5% revenue growth

EPS GrowthGrowth
-9.2%2/10

Earnings declined 9.2%

RMD1 concerns · Avg: 4.0/10
EPS GrowthGrowth
2.4%4/10

2.4% earnings growth

Comparative Analysis Report

WallStSmart Research

Bull Case : HOLX

The strongest argument for HOLX centers on Operating Margin.

Bull Case : RMD

The strongest argument for RMD centers on Operating Margin, Altman Z-Score, Return on Equity. Profitability is solid with margins at 27.0% and operating margin at 30.9%. PEG of 1.33 suggests the stock is reasonably priced for its growth.

Bear Case : HOLX

The primary concerns for HOLX are PEG Ratio, P/E Ratio, Revenue Growth.

Bear Case : RMD

The primary concerns for RMD are EPS Growth.

Key Dynamics to Monitor

HOLX profiles as a value stock while RMD is a mature play — different risk/reward profiles.

RMD carries more volatility with a beta of 0.77 — expect wider price swings.

RMD is growing revenue faster at 8.6% — sustainability is the question.

RMD generates stronger free cash flow (1.6B), providing more financial flexibility.

Bottom Line

RMD scores higher overall (65/100 vs 51/100), backed by strong 27.0% margins. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Hologic Inc

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

Hologic, Inc. is a medical technology company primarily focused on women's health; it sells medical devices for diagnostics, surgery, and medical imaging.

Visit Website →

ResMed Inc

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

ResMed is a San Diego, California-based medical equipment company. It primarily provides cloud-connectable medical devices for the treatment of sleep apnea (such as CPAP devices and masks), chronic obstructive pulmonary disease (COPD), and other respiratory conditions.

Visit Website →

Want to dig deeper into these stocks?